EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE

FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE0 个研究点开始时间: 2012年3月14日最近更新: 2014年1月27日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE

暂无简介。

•° males and females aged between 65 and 80 °patients affected by Parkinson's disease following international guidelines, in treatment with levodopa and/or dopamine agonists ° spine or femoral neck BMD T-score (using DXA) at least < -2.5 ° previuos low adherence or gastric/oesophageal intolerance to oral bisphosphonates stopped at least 3 months before the enrolment written informed consent to the treatment
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•°patients in efficaciuos treatment with oral bisphosphonates or SERMS °patients in treatment with oestrogens, glucocorticoids, calcitonin during last 12 months ° previous femural osteoporotic fractures °patients affected by bone metabolic diseses othe than osteoporosis, osteomalacia, hyperparathyroidism, hypocalcemia ° affected by renal, cardiovascular or neoplastic diseases ° affected by neurological diuseases other than Parkinson's disease ° affected by Parkinson's disease at stages 0 and 5 following Hoehn and Yahr criteria

发起方